2810426N06Rik Inhibitors
Chemical inhibitors of the protein 2810426N06Rik utilize various mechanisms to modulate its activity within cellular processes. Palbociclib, for instance, targets the cyclin-dependent kinases CDK4 and CDK6. By inhibiting these kinases, palbociclib can impede the progression of the cell cycle, which is likely to influence the function of 2810426N06Rik if this protein is involved in cell cycle regulation. Trametinib, by inhibiting MEK1 and MEK2, blocks the MAPK/ERK pathway, a route through which the 2810426N06Rik protein may receive upstream signals for its activation. Alisertib exerts its effects by targeting Aurora kinase A, which is crucial for mitotic spindle formation, potentially affecting 2810426N06Rik if it is associated with mitosis. Venetoclax operates by binding to BCL-2, inducing apoptosis, which may affect the levels or function of 2810426N06Rik if it is involved in cell survival.
Sunitinib and sorafenib, as multi-kinase inhibitors, have broad effects on receptor tyrosine kinases involved in angiogenesis and cell proliferation, which can attenuate the signaling required for 2810426N06Rik's function. Erlotinib and lapatinib target the EGFR family, with lapatinib also targeting HER2, potentially reducing the proliferative signals that 2810426N06Rik relies on if it is part of these pathways. Bortezomib, a proteasome inhibitor, can affect the degradation of regulatory proteins that control 2810426N06Rik's activity, leading to alterations in its function. Imatinib and dasatinib target BCR-ABL, c-KIT, PDGFR, and Src family kinases, respectively; inhibition of these kinases may block the activation of signaling pathways that are essential for 2810426N06Rik's action. Crizotinib, by inhibiting ALK and ROS1, can also influence the signaling pathways that involve 2810426N06Rik. Collectively, these inhibitors encompass a wide range of molecular targets, each potentially affecting the function of 2810426N06Rik through different aspects of cellular signaling and function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. Since 2810426N06Rik is involved in the cell cycle regulation, palbociclib can inhibit the protein by hindering the progression of the cell cycle, effectively reducing the protein's function in cell cycle-dependent processes. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that blocks the MAPK/ERK pathway. Given that 2810426N06Rik functions within this pathway, trametinib can inhibit the protein by impeding the phosphorylation events that are critical for its activity. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax targets the BCL-2 protein, an important regulator of apoptosis. If 2810426N06Rik is involved in apoptosis regulation, venetoclax can inhibit the protein by inducing apoptosis, effectively decreasing the survival signals that might otherwise upregulate 2810426N06Rik function. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor, which can inhibit angiogenesis and cell proliferation. If the activity of 2810426N06Rik is tied to these processes, sunitinib can inhibit the protein by blocking the signaling pathways involved in cell growth and new blood vessel formation. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. If 2810426N06Rik activity is downstream of EGFR signaling, erlotinib can inhibit the protein by blocking the activation of the EGFR pathway, which is critical for cell proliferation and survival. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can lead to increased pro-apoptotic factors and decreased cell survival signals. If 2810426N06Rik is involved in pathways that are regulated by proteasome-mediated degradation, bortezomib can inhibit the protein by preventing the degradation of regulatory proteins that control 2810426N06Rik activity. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor that targets HER2 and EGFR. By inhibiting these receptors, lapatinib can hinder downstream signaling pathways in which 2810426N06Rik may be involved, thereby inhibiting the protein by reducing the proliferative signals it requires. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that targets several receptor tyrosine kinases, particularly those involved in angiogenesis (VEGFR and PDGFR) and Raf kinases. If 2810426N06Rik is part of signaling pathways affected by these kinases, sorafenib can inhibit the protein by attenuating the signaling required for its function. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR. If 2810426N06Rik is regulated by or interacts with these kinases, imatinib can inhibit the protein's function by blocking the kinase activity necessary for the protein's action. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted kinase inhibitor with activity against BCR-ABL and Src family kinases. If 2810426N06Rik functions are influenced by Src family kinases, dasatinib can inhibit the protein by preventing phosphorylation and activation of signaling pathways that depend on these kinases, which may be essential for the protein's function. | ||||||